CHAELEENA LADD: Open Payments
NPI 1518400035 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,850 in 142 payments from 19 companies in 2025. Trend: 2023 $3,214 · 2024 $2,653 · 2025 $2,850
Food & beverage: $2,759Education: $91
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 29 | $645 |
| GlaxoSmithKline, LLC. | 24 | $279 |
| United Therapeutics Corporation | 11 | $264 |
| Grifols USA, LLC | 8 | $191 |
| Actelion Pharmaceuticals US, Inc. | 6 | $188 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $182 |
| Merck Sharp & Dohme LLC | 7 | $173 |
| Verona Pharma, Inc. | 8 | $149 |
| ANI Pharmaceuticals, Inc. | 4 | $128 |
| GENZYME CORPORATION | 6 | $123 |
Products named: BREZTRI, DUPIXENT, FASENRA, Prolastin-C Liquid, Tyvaso, Ohtuvayre, TRELEGY ELLIPTA, NUCALA.
Industry payments across MS — which companies pay providers there.
